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Abstract
Pancreatic ductal adenocarcinoma (PDAC) has an ex-
tremely poor prognosis. To improve the prognosis, nov-
el molecular markers and targets for earlier diagnosis
and adjuvant and/or neoadjuvant treatment are needed.
Recent advances in human genome research and high-
throughput molecular technologies make it possible to
cope with the molecular complexity of malignant tu-
mors. With DNA array technology, mRNA expression
levels of thousand of genes can be measured simulta-
neously in a single assay. As several studies using
microarrays in PDAC have already been published, this
review attempts to compare the published data and
therefore to validate the results. In addition, the applied
techniques are discussed in the context of pancreatic
malignancies.
Copyright © 2004 S. Karger AG, Basel and IAP
Introduction
Pancreatic cancer is the fourth leading cause of cancer
death in the United States [1] and the sixth leading cause
of cancer deaths in Germany [2]. The World Health Orga-
nization estimates 112,000 cases worldwide for the year
2000. It is a common disease with a very poor prognosis.
The frequent diagnosis at late stages of the disease limits
the role of surgery as a curative modality. Despite ad-
vanced technologies in therapy and diagnostics, the 5-year
survival rate remains less than 5% and generally the sur-
vival time after diagnosis is 3–6 months. About 95% of
pancreatic cancers are ductal adenocarcinomas (PDACs),
5% are islet cell tumors. Development of pancreatic can-
cer is a multi-stage process resulting from the accumula-
tion of genetic changes in somatic cells. Activating muta-
tions of the k-ras oncogene are found in virtually all cases
of pancreatic cancer and are early events in tumori-
genesis [3–6]. Mutations in tumor suppressors, such as
p16INK4a [7–9], p53 [8, 10–12] and DPC4/SMAD4 [13],
appear to occur as a second step in advanced tumorigene-
sis. The identification of alterations in gene expression
that occur during tumorigenesis may provide information
for the early diagnosis of pancreatic cancer. Gene expres-
sion can be analyzed by various methods: differential dis-
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play RT-PCR; representational difference analysis; se-
quencing expressed sequence tags (ESTs) or short frag-
ment tags produced during a process called sequential
analysis of gene expression (SAGE), and finally DNA-
microarray technology. All these methods were developed
for comparative studies allowing a systematic screening
for molecular differences at the level of mRNA expression
in different cells or tissues.
Differential display is based on an amplification of
messenger RNA 3)-termini using an anchored oligo-dT
primer at one end and a short primer with an arbitrary
sequence at the other end. The amplified cDNAs, labelled
with a radioisotope, are then separated on a denaturing
polyacrylamide gel and visualized by autoradiography or
phosphorimaging. Side-by-side comparison of mRNA
species from two or more related samples allows an identi-
fication of both up- and downregulation of the genes of
interest [14].
Representational differential analysis [15] and related
procedures take advantage of the competition between
identical sequences for complementary DNA. In combi-
nation with a selective PCR amplification step, this allows
a subtractive and kinetic enrichment of genes that are dif-
ferentially transcribed in two samples. Such studies iden-
tified many genes that are over- or underexpressed in pan-
creatic cancer tissue [16, 17]. The procedure has the
advantage of selecting with all transcripts; it lacks the abil-
ity of (easy) quantification, however.
The availability of large EST and SAGE-tag libraries
make comparative EST or SAGE-tag counting possible.
Libraries of identical sources can be pooled and the occur-
rence of sequences that are specific for a particular gene is
determined by sequencing. Also, large databases of this
kind exist (e.g., http://www.ncbi.nlm.nih.gov/) and can be
used for in silico analyses. Tag counting has been success-
fully applied to pancreatic cancer [18]. Both methods,
however, lack the potential for high-throughput analyses
on a routine basis.
Recent developments in human genome research and
technical advances in molecular biology procedures made
DNA microarray technology the method of choice for
gene expression analyses. This technology is capable to
cope with the molecular complexity of malignant tumors,
since the mRNA expression levels of thousands of genes
can be measured simultaneously in a single assay. By such
means, it is now possible to distinguish tumor subclasses
by gene expression profiles and to identify new diagnostic
and prognostic biomarkers as well as potential therapeutic
targets.
Background of Chip Technology
The power of DNA microarrays as experimental tools
derives from the specificity and relatively strong affinity
of duplex formation of complementary sequences. In
1965, Gillespie and Spiegelman [19] observed that single-
stranded DNA binds strongly to nitrocellulose mem-
branes in a way that prevents the strands from re-associat-
ing with each other, but permits hybridization to comple-
mentary RNA. Development of a blotting technique by
Southern [20] proved to be a milestone in assaying nucleic
acids. Clone filter arrays were introduced by Lerach and
colleagues [21] permitting a reverse analysis format in
transcript analysis. Rather than studying global prepara-
tions of nucleic acids sequentially with individual probes,
they presented the unique DNA content of very many
recombinant library clones in an ordered manner, to
which global RNA samples could be hybridized. The
resulting parallelism in data production was a crucial step
toward genome-wide analyses, as indicated by early re-
sults from pancreatic cancer samples done by Gress et al.
[22]. In situ synthesis of oligonucleotide arrays [23, 24]
and the arraying of prefabricated fragments of nucleic
acids on glass surfaces [25] made such arrays more readily
available.
Today, several options exist on how to create microar-
rays. Frequently, PCR products are arrayed in-house
using spotting robots [26–28]. Also, a broad assortment of
commercially available arrays exists [29]. Currently one
of the most frequently used systems for global transcrip-
tional profiling analysis is that from Affymetrix. Their
arrays are produced by photolithographically controlled
in situ oligonucleotide synthesis. Up to one million probes
could be synthesized on an array of 1.28 ! 1.28 cm [30].
A big disadvantage of this system is the fact that the chip
design cannot be modified easily. Especially for tailor-
made arrays assaying only the genes relevant to the
respective disease, global arrays represent an expensive
overkill. However, newly developed systems, such as the
Geniom device developed by febit [31] for example, allow
a flexible design of the probe composition. Based on elec-
tronically controlled micromirrors, the time-consuming
and expensive production of photolithographic masks is
avoided. Therefore, microarrays of any probe content can
be produced on site, nevertheless using the high resolution
of photo-controlled synthesis; only a file of oligonucleo-
tide sequences is required. Also, the chip can be subdivid-
ed into up to eight separate entities, thereby adapting the
number of probe molecules to the actual need of the
respective analysis.
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Table 1. Published PDAC microarray analyses
Author Type of array Number
of genes
Tissues, number
T N CP CL
Micro-
dissection
Friess et al. [44], 2001 Oligonucleotides F5,600 8 8
(organ donors)
8 – No
Han et al. [46], 2002 cDNA PCR products F5,289 1
(commercial)
– 8 No
Iacobuzio-Donahue et al. [47], 2002 Oligonucleotides F12,000 14 11 – 8 No
Tan et al. [48], 2003 cDNA PCR products F12,800 6 6 – – No
Iacobuzio-Donahueet al. [49], 2003 cDNA PCR products F30,000 17 5 – 14 No
Logsdon et al. [50], 2003 Oligonucleotides F5,600 10 5 5 7 No
Grützmann et al. [51], 2003 Oligonucleotides F3,000 7 3 – 5 Yes
Crnogorac-Jurcevic et al. [52], 2003 cDNA PCR products F9,000 9 4 – 20 No
Friess et al. [53], 2003 Oligonucleotides F5,600 8 8 8 – No
Iacobuzio-Donahue et al. [54], 2003 Oligonucleotides F33,000 26 25
(+25 normal
duodenal mucosa)
7 13 No
Terris et al. [55], 2002 cDNA PCR products F4,992 13a 4b – 1
T = Tumor tissues; N = normal tissues; CP = chronic pancreatitis; CL = cell lines.
a Intraductal papillary-mucinous tumor.
b A pool of normal pancreas was prepared from 2 donor tissues and 2 normal adjacent pancreatic parenchymas from ampullary tumors.
Beyond transcriptional profiling, there is a large vari-
ety of other analysis types that can be performed on
microarrays. The detection of single nucleotide polymor-
phisms [32], comparative genomic hybridization [33] or
studies on epigenetic variation [34] for example, could
become as important for diagnosis and prognosis as the
analysis on the transcript level.
Advances in Research on Pancreatic Cancer
Using Microarray Technology
Gene expression profiling has been applied to a variety
of tumors such as breast [35], colon [36–38], prostate [39],
esophagus [40] and the stomach [41]. In pancreatic can-
cer, several analyses using methods other than microar-
rays were performed to elucidate gene expression changes
[17, 18, 42–45]. In addition, 11 studies of pancreatic
tumors by DNA microarray technology have been pub-
lished to date [44, 46–55] (table 1). These studies identi-
fied large sets of new class-II cancer genes [56] revealing
dysregulation at the level of transcription. However, as
noticed earlier [57], the published results are not easily
comparable, because of the different hybridization plat-
forms and data analysis procedures that were applied. In
addition, the samples were not picked from a defined
cohort of patients. Nevertheless, this article aims at an ini-
tial cross-validation of the published data on genes that
are differentially expressed in normal and neoplastic pan-
creatic cells in order to define new markers or potentially
interesting target entities, which are urgently required for
an improved diagnosis and treatment.
Microarray Technology: How to Find
Differentially Expressed Genes
Performing microarray experiments entails a twofold
challenge. First and foremost is the correct performance of
the experimental part. Already the preparation of the RNA
is not easily performed and most critical to all subsequent
steps especially in pancreatic tissues. Any difference in
how the tissue is being isolated will immediately translate
into changes in the transcript level. Given the fact that
some mRNA molecules have a half life of a few seconds
only, it is very likely that artificial variations will be seen
for some mRNA molecules, regardless of the method
applied. It is critical and possible, however, to freeze, liter-
ally, the transcript status of a tissue as quickly as technical-
ly possible in order to extract meaningful data.
Also the second part, the identification of significantly
differentially transcribed genes from the total information
generated on microarrays, is not trivial. To date, there is
no gold standard for performing these bio-informatic
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Table 2. Useful databases and software tools
Name URL Description
ArrayExpress http://www.ebi.ac.uk/arrayexpress/ Data collection and software source
GEO http://www.ncbi.nlm.nih.gov/geo/ Data collection and software source
SMD http://genome-www5.stanford.edu/ Data collection and software source
M-CHiPS http://www.mchips.org Data collection and software source
SAM http://www-stat.stanford.edu/Ftibs/SAM/ Data analysis software
Base http://base.thep.lu.se/ Open source database software
GenePattern http://www-genome.wi.mit.edu/cancer/software/software.html Data analysis software
BioConductor http://biosun1.harvard.edu/complab/dchip/ Software source
analyses, but some general rules are emerging. Normaliza-
tion, for example, is mostly performed globally based on
an average intensity level on a microarray. Only rarely is
it based on a selection of genes which are considered to be
not differentially expressed [58, 59]. The former process is
mostly much more robust. Still, it may lead to false inter-
pretation [60]. Also, the definition of a globally applicable
threshold is impossible, since such a value depends on all
experimental factors and therefore differs from experi-
ment to experiment. Only statistical analyses, such as the
‘significance analysis of microarrays’ package [61], permit
a sensible analysis. Minimal standards on how to perform
transcriptional profiling analyses on microarrays were
discussed and defined by the MGED consortium
(www.mged.org) [62]. Next to commercial software, sev-
eral program packages exist that are freely available to
academic users (table 2).
Gene Validation
If performed according to strict statistical procedures,
the measurement of differential gene expression with mi-
croarrays can be a very reliable method. In a global setting,
cross-validation of the results with other array experiments
enables an evaluation of data quality, simply by increasing
the number of experiments that are taken into account.
The feasibility of this approach was demonstrated by
Rhodes et al. [63] and is actually the aim of this review with
respect to pancreatic cancer. For individual transcripts,
quantitative PCR [64] is an even more precise instrument
for the measurement of differential RNA levels but lacks
power with respect to throughput. Last, it is well known
that variations in RNA level do not necessarily correlate
with variations in protein level. Therefore, analysis of the
actual protein expression may eventually supersede trans-
cript profiling, at least for target identification.
Transcript Variations in Pancreatic Tumors
The results from several groups show that gene expres-
sion profiling of pancreatic tumors using high-density
arrays yields meaningful data, if performed appropriately.
In total, 978 genes were found to be differentially tran-
scribed in pancreatic tumors. Table 3 combines the re-
sults of the currently available publications listed in
table 1. Only genes that were found in at least 2 studies are
listed, producing a catalogue of 148 genes. There are sev-
eral potential reasons for this low concordance between
the studies. First, the type, histology and number of sam-
ples used (i.e., established cell lines or human pancreatic
cancer cells) differed widely. Some studies included tu-
mors other than PDAC, like neuroendocrine tumors or
tumors of the papilla of Vater. This degree of variation is
most likely true also for the samples representing normal
tissues (commercially available RNA, normal tissue from
resected pancreatic tumors or donor organs). Second,
microdissection was applied by one group [51] while most
studies were performed on whole tissue samples or cell
lines. In cell lines, in vitro conditions may induce changes
in gene expression that are not present in vivo. Pancreatic
tumor specimens contain different cell types, including
ductal, acinar, islet, inflammatory and nerve cells as well
as fibrocytic elements. When whole tissues are used, the
expression profiles represent both the variations in tumor
and the adjacent non-neoplastic tissue. Third, different
arrays and array technologies may lead to different gene
expression results. As Kuo et al. [65] demonstrated, there
can be poor correlation when the same samples are ana-
lyzed with two technologies (e.g., cDNA versus oligonu-
cleotide microarrays). Fourth, statistical analysis and data
mining procedures differed between the studies. Last,
quite a few of the variations could well be due to individu-
al reactions of the patients rather than being directly can-
cer-related.
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Table 3. Genes shown to be differentially transcribed in pancreatic tumors using microarray technology
UG_ID a b c d e f g h i j Counts
T N
Acc Name Symbol
Hs.2962 T T T T T T T 7 0 NM_005980 S100 calcium-binding protein P S100P
Hs.204238 T T T T T 5 0 NM_005564 Lipocalin 2 (oncogene 24p3) LCN2
Hs.287558 T T T T T N 5 1 NM_000700 Annexin A1 ANXA1
Hs.54451 T T T T T 5 0 NM_005562 Laminin-Á2 LAMC2
Hs.154036 T T T T 4 0 NM_003311 Pleckstrin homology-like domain,
family A, member 2
PHLDA2
Hs.179657 T T T T 4 0 NM_002659 Plasminogen activator, urokinase receptor PLAUR
Hs.194691 T T T T 4 0 NM_003979 Retinoic acid induced 3 RAI3
Hs.251754 T T T T 4 0 NM_003064 Secretory leukocyte protease inhibitor
(anti-leukoproteinase)
SLPI
Hs.408864 T T T T 4 0 NM_000574 Decay-accelerating factor for complement1 DAF
Hs.417004 T T T T 4 0 NM_005620 S100 calcium-binding protein A11
(calgizzarin)
S100A11
Hs.82237 T T T T 4 0 NM_012101 Tripartite motif-containing 29 TRIM29
Hs.82422 T T T T 4 0 NM_001747 Capping protein (actin filament), gelsolin-like CAPG
Hs.103707 T T T 3 0 XM_039877 Mucin-5, subtypes A and C,
tracheobronchial/gastric
MUC5AC
Hs.111554 T T T 3 0 NM_005737 ADP-ribosylation factor-like 7 ARL7
Hs.1355 T T T 3 0 NM_001910 Cathepsin E CTSE
Hs.139851 T T T 3 0 BC005256 Caveolin 2 CAV2
Hs.155419 T T T 3 0 NM_001197 BCL2-interacting killer (apoptosis-inducing) BIK
Hs.156346 T T T 3 0 NM_001067 Topoisomerase (DNA) II ·, 170 kDa TOP2A
Hs.169902 T T T 3 0 NM_006516 Solute carrier family 2 (facilitated
glucose transporter), member 1
SLC2A1
Hs.184510 T T T 3 0 NM_006142 Stratifin SFN
Hs.220529 T T T 3 0 NM_004363 Carcinoembryonic antigen-related
cell adhesion molecule 5
CEACAM5
Hs.2442 T T T 3 0 NM_003816 Disintegrin and metalloproteinase
domain 9 (meltrin-Á)
ADAM9
Hs.2785 T T T 3 0 NM_000422 Keratin 17 KRT17
Hs.292738 T T T 3 0 NM_001175 Rho GDP dissociation inhibitor (GDI) ß ARHGDIB
Hs.2979 T T T 3 0 NM_005423 Trefoil factor 2 (spasmolytic protein 1) TFF2
Hs.301350 T T T 3 0 NM_021910 FXYD domain containing ion transport
regulator 3
FXYD3
Hs.309517 T T T 3 0 NM_002276 Keratin 19 KRT19
Hs.323733 T T T 3 0 NM_004004 Gap junction protein, ß2, 26 kDa
(connexin 26)
GJB2
Hs.348553 T T T 3 0 AK027130 Immortalization-upregulated protein IMUP
Hs.362731 T T T 3 0 NM_013451 fer-1-like 3, myoferlin (C. elegans) FER1L3
Hs.376874 T T T 3 0 NM_002245 Potassium channel, subfamily K, member 1 KCNK1
Hs.418138 T T T 3 0 NM_002026 Fibronectin 1 FN1
Hs.423190 T T T 3 0 NM_001311 Cysteine-rich protein 1 (intestinal) CRIP1
Hs.450230 T T T 3 0 NM_000598 Insulin-like growth factor-binding protein 3 IGFBP3
Hs.624 T T T 3 0 NM_000584 Interleukin-8 IL8
Hs.83758 T T T 3 0 NM_001827 CDC28 protein kinase regulatory subunit 2 CKS2
Hs.85266 T T T 3 0 NM_000213 Integrin-ß4 ITGB4
Hs.112341 T T 2 0 NM_002638 Protease inhibitor 3, skin-derived (SKALP) PI3
Hs.115166 T T 2 0 NM_144777 Sciellin SCEL
Hs.118400 T T 2 0 NM_003088 Fascin homolog 1, actin-bundling protein
(Strongylocentrotus purpuratus)
FSCN1
Hs.126222 T T 2 0 NM_005717 Actin-related protein 2/3 complex,
subunit5, 16 kDa
ARPC5
Hs.127799 T T 2 0 NM_001165 Baculoviral IAP repeat-containing 3 BIRC3
Hs.128453 T T 2 0 NM_001463 Frizzled-related protein FRZB
Hs.136348 T T 2 0 NM_006475 Osteoblast-specific factor-2 (fasciclin-I-like) OSF-2
Hs.139389 T T 2 0 NM_001323 Cystatin E/M CST6
Hs.1600 T T 2 0 NM_012073 Chaperonin-containing TCP1, subunit 5 (Â) CCT5
Hs.172928 T T 2 0 NM_000088 Collagen type I, ·1 COL1A1
Hs.179729 T T 2 0 NM_000493 Collagen type X, ·1(Schmid
metaphyseal chondrodysplasia)
COL10A1
Hs.180909 T T 2 0 NM_002574 Peroxiredoxin 1 PRDX1
Hs.180919 T T 2 0 NM_002166 Inhibitor of DNA-binding 2, dominant
negative helix-loop-helix protein
ID2
Hs.191842 T T N 2 1 NM_001793 Cadherin 3, type 1, P-cadherin (placental) CDH3
Hs.198281 T T N 2 1 NM_182470 Pyruvate kinase, muscle PKM2
Hs.211573 T T 2 0 NM_005529 Heparan sulfate proteoglycan 2 (perlecan) HSPG2
+
592 Pancreatology 2004;4:587–597 Brandt/Grützmann/Bauer/Jesnowski/
Ringel/Löhr/Pilarsky/Hoheisel
Table 3 (continued)
UG_ID a b c d e f g h i j Counts
T N
Acc Name Symbol
Hs.21486 T T 2 0 NM_007315 Signal transducer and activator of
transcription 1, 91 kDa
STAT1
Hs.21858 T T 2 0 NM_006216 Serine (or cysteine) proteinase
inhibitor, clade E2
SERPINE2
Hs.223025 T T 2 0 NM_006868 RAB31, member RAS oncogene family RAB31
Hs.226391 T T 2 0 NM_006408 Anterior gradient-2 homolog
(Xenopus laevis)
AGR2
Hs.227806 T T 2 0 NM_170692 RAS protein activator-like 2 RASAL2
Hs.22941 T T 2 0 NM_020792 KIAA1363 protein KIAA1363
Hs.232115 T T 2 0 NM_000089 Collagen type-I, ·2 COL1A2
Hs.235782 T T 2 0 NM_016354 Solute carrier organic anion transporter
family, member 4A1
SLCO4A1
Hs.23881 T T 2 0 NM_005556 Keratin 7 KRT7
Hs.241579 T T 2 0 NM_001235 Serine (or cysteine) proteinase inhibitor,
clade H3
SERPINH1
Hs.2499 T T 2 0 NM_002741 Protein kinase C-like 1 PRKCL1
Hs.250641 T T 2 0 NM_003290 Tropomyosin 4 TPM4
Hs.250822 T T 2 0 NM_003600 Serine/threonine kinase 6 STK6
Hs.25338 T T 2 0 NM_007173 Protease, serine, 23 SPUVE
Hs.265829 T T N 2 1 NM_002204 Integrin-·3 (antigen CD49C, ·3 subunit of
VLA-3 receptor)
ITGA3
Hs.268571 T T 2 0 NM_001645 Apolipoprotein C-I APOC1
Hs.272822 T T 2 0 NM_003707 RuvB-like 1 (E. coli) RUVBL1
Hs.275243 T T 2 0 NM_014624 S100 calcium-binding protein A6 (calcyclin) S100A6
Hs.278613 T T 2 0 NM_005532 Interferon-·-inducible protein 27 IFI27
Hs.278896 T T 2 0 NM_019075 UDP glycosyltransferase-1 family,
polypeptide A10
UGT1A10
Hs.279651 T T 2 0 NM_006533 Melanoma inhibitory activity MIA
Hs.283565 T T 2 0 NM_005438 FOS-like antigen 1 FOSL1
Hs.334562 T T 2 0 NM_001786 Cell division cycle 2, G1 to S and G2 to M CDC2
Hs.348935 N T T 2 1 NM_020070 Immunoglobulin-Ï-like polypeptide 1 IGLL1
Hs.352018 T T 2 0 NM_000593 Transporter 1, ATP-binding cassette,
subfamily B (MDR/TAP)
TAP1
Hs.3628 T T 2 0 NM_145686 Mitogen-activated protein kinase kinase
kinase kinase 4
MAP4K4
Hs.387579 T T 2 0 NM_001769 CD9 antigen (p24) CD9
Hs.387725 T T 2 0 NM_002203 Integrin-·2 (CD49B, ·2 subunit of
VLA-2 receptor)
ITGA2
Hs.38972 T T 2 0 NM_005727 Tetraspan 1 TSPAN-1
Hs.406475 T T 2 0 NM_002345 Lumican LUM
Hs.406515 T T 2 0 NM_000903 NAD(P)H dehydrogenase, quinone 1 NQO1
Hs.411701 T T 2 0 NM_194327 Lectin, galactoside-binding, soluble, 3
(galectin 3)
LGALS3
Hs.411958 T T 2 0 NM_018950 Major histocompatibility complex, class I, F HLA-F
Hs.419776 T T 2 0 NM_139207 Nucleosome assembly protein-1-like 1 NAP1L1
Hs.434488 T T 2 0 NM_004385 Chondroitin sulfate proteoglycan 2 (versican) CSPG2
Hs.436718 T T 2 0 NM_002483 Carcinoembryonic antigen-related cell
adhesion molecule 64
CEACAM6
Hs.436983 T T 2 0 NM_000228 Laminin-ß3 LAMB3
Hs.445226 T T 2 0 NM_004240 Thyroid hormone receptor interactor 10 TRIP10
Hs.512682 T T 2 0 NM_001712 Carcinoembryonic antigen-related cell
adhesion molecule 15
CEACAM1
Hs.512708 T T 2 0 NM_004613 Transglutaminase 26 TGM2
Hs.512711 T T 2 0 NM_000365 Triosephosphate isomerase 1 TPI1
Hs.55279 T T 2 0 NM_002639 Serine (or cysteine) proteinase inhibitor,
clade B (ovalbumin), member 5
SERPINB5
Hs.56319 T T 2 0 NM_001899 Cystatin S CST4
Hs.727 T T 2 0 NM_002192 Inhibin-ßA (activin A, activin AB
·-polypeptide)
INHBA
Hs.72925 T T 2 0 NM_003475 Chromosome-11 open reading frame 13 C11orf13
Hs.75318 T T 2 0 NM_006000 Tubulin-·1 (testis specific) TUBA1
Hs.75360 T T 2 0 NM_001873 Carboxypeptidase E CPE
Hs.77274 T T 2 0 NM_002658 Plasminogen activator, urokinase PLAU
Hs.77348 T T 2 0 NM_000860 Hydroxyprostaglandin dehydrogenase 15
(NAD)
HPGD
Hs.77515 T T 2 0 NM_002224 Inositol 1,4,5-triphosphate receptor, type 3 ITPR3
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Table 3 (continued)
UG_ID a b c d e f g h i j Counts
T N
Acc Name Symbol
Hs.79033 T T 2 0 NM_012413 Glutaminyl-peptide cyclotransferase
(glutaminyl cyclase)
QPCT
Hs.79440 T T 2 0 NM_006547 IGF-II mRNA-binding protein 3 IMP-3
Hs.82101 T T 2 0 NM_007350 Pleckstrin homology-like domain,
family A, member 1
PHLDA1
Hs.82109 T T 2 0 NM_002997 Syndecan 1 SDC1
Hs.82961 T T 2 0 NM_003226 Trefoil factor 3 (intestinal) TFF3
Hs.83450 T T N 2 1 NM_198129 Laminin-·3 LAMA3
Hs.83753 T T 2 0 NM_003091 Small nuclear ribonucleoprotein
polypeptides B and B1
SNRPB
Hs.85226 T T 2 0 NM_000235 Lipase A, lysosomal acid, cholesterol
esterase (Wolman disease)
LIPA
Hs.86947 T T 2 0 NM_001109 Disintegrin and metalloproteinase domain 8 ADAM8
Hs.87268 T T N 2 1 NM_001630 Annexin A8 ANXA8
Hs.89434 T T 2 0 NM_080881 Drebrin 1 DBN1
Hs.98428 T T 2 0 NM_156036 Homeo box B6 HOXB6
Hs.123107 N N N 0 3 NM_002257 Kallikrein 1, renal/pancreas/salivary KLK1
Hs.199695 N N N 0 3 NM_014573 Hypothetical protein MAC30 MAC30
Hs.26126 N N N 0 3 NM_182848 Claudin 10 CLDN10
Hs.375108 N N N 0 3 NM_013230 CD24 antigen (small cell lung carcinoma
cluster 4 antigen)
CD24
Hs.409223 N N N 0 3 NM_006280 Signal sequence receptor, ‰
(translocon-associated protein ‰)
SSR4
Hs.423 N N N 0 3 NM_138938 Pancreatitis-associated protein PAP
Hs.75335 N N N 0 3 NM_001482 Glycine amidinotransferase
(L-arginine:glycine amidinotransferase)
GATM
Hs.992 N N N 0 3 NM_000928 Phospholipase A2, group IB (pancreas) PLA2G1B
Hs.25647 N N T 1 2 NM_005252 v-fos FBJ murine osteosarcoma viral
oncogene homolog
FOS
Hs.107 N N 0 2 NM_004467 Fibrinogen-like 1 FGL1
Hs.1239 N N 0 2 NM_001150 Alanyl (membrane) aminopeptidase7 ANPEP
Hs.1340 N N 0 2 NM_001832 Colipase, pancreatic CLPS
Hs.169234 N N 0 2 NM_015849 Pancreatic elastase IIB ELA2B
Hs.169900 N N 0 2 NM_003819 Poly(A)-binding protein, cytoplasmic 4
(inducible form)
PABPC4
Hs.181300 N N 0 2 NM_005065 Sel-1 suppressor of lin-12-like (C. elegans) SEL1L
Hs.2879 N N 0 2 NM_001868 Carboxypeptidase A1 (pancreatic) CPA1
Hs.388004 N N 0 2 NM_000687 S-adenosylhomocysteine hydrolase AHCY
Hs.407856 N N 0 2 NM_003122 Serine protease inhibitor, Kazal type 1 SPINK1
Hs.410578 N N 0 2 NM_000918 Procollagen-proline, 2-oxoglutarate
4-dioxygenase8
P4HB
Hs.422542 N N 0 2 NM_004132 Hyaluronan-binding protein 2 HABP2
Hs.433391 N N 0 2 NM_005950 Metallothionein 1G MT1G
Hs.433750 N N 0 2 NM_182917 Eukaryotic translation initiation factor 4Á, 1 EIF4G1
Hs.433797 N N 0 2 NM_002885 RAP1, GTPase-activating protein 1 RAP1GA1
Hs.435699 N N 0 2 NM_002771 Protease, serine, 3 (mesotrypsin) PRSS3
Hs.436042 N N 0 2 NM_000609 Chemokine (C-X-C motif) ligand 12
(stromal cell-derived factor 1)
CXCL12
Hs.437638 N N 0 2 NM_005080 X-box binding protein 1 XBP1
Hs.444159 N N 0 2 NM_003627 Solute carrier family 43, member 1 SLC43A1
Hs.74502 N N 0 2 NM_001906 Chymotrypsinogen B1 CTRB1
Hs.75462 N N 0 2 NM_006763 BTG family, member 2 BTG2
Hs.79361 N N 0 2 NM_002774 Kallikrein 6 (neurosin, zyme) KLK6
Hs.79428 N N 0 2 NM_004052 BCL2/adenovirus E1B 19 kDa interacting
protein 3
BNIP3
Hs.80206 N N 0 2 NM_000402 Glucose-6-phosphate dehydrogenase G6PD
Hs.81131 N N 0 2 NM_000156 Guanidinoacetate N-methyltransferase GAMT
1 CD55, Cromer blood group system.
2 Nexin, plasminogen activator inhibitor type 1, member 2.
3 Heat shock protein 47, member 1, collagen binding protein 1.
4 Non-specific cross-reacting antigen.
5 Biliary glycoprotein.
6 C polypeptide, protein-glutamine-Á-glutamyltransferase.
7 Aminopeptidase N, aminopeptidase M, microsomal aminopeptidase,
CD13, p150.
8 (Proline 4-hydroxylase), ß-polypeptide (protein disulfide isomerase; thy-
roid hormone-binding protein p55).
a = Iacobuzio-Donahue CR2003 [54]; b = Iacobuzio-Donahue AJP2002
[47]; c = Friess CMLS2003 [53]; d = Logsdon CR2003 [50]; e = Iacobuzio-
Donahue AJP2003 [49]; f = Han CR2002 [46]; g = Tan WJG2003 [48]; h =
Grützmann VA2003 [51]; i = Crnogorac-Jurcevic JP2003 [52]; j = Terris
AJP2002 [55]; T = overexpressed in tumor tissue; N = overexpressed in nor-
mal tissue.
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The majority of the 148 genes (n = 115) were found to
be upregulated in pancreatic tumors. One gene, S100 cal-
cium-binding protein P, was upregulated in 7 of the 10
studies. Three genes, among them annexin-A1, lipoca-
lin-2 and laminin-Á2, were upregulated in 5 studies. Eight
genes, including gelsolin-like protein, S100 calcium-bind-
ing protein A11, plasminogen activator, urokinase recep-
tor and retinoic acid induced 3, were overexpressed in 4
studies. Three of 10 was scored by 25 genes, among them
ADAM9. Its expression was very recently found to be an
independent marker of shortened survival after curative
resection of PDAC [66]. The majority of genes (in total
78) were upregulated in 2 studies. Among the genes that
were overexpressed in PDAC, 9 genes including keratin-7
[67], stratifin [68] and CD55 [69] had been previously
implicated in PDAC. These genes, which have also been
identified by other profiling methods, confirm the validi-
ty of microarray-based expression profiling. Moreover, 14
of the upregulated genes were known from microarray
analyses on other cancers. This includes versican (overex-
pressed in malignant melanomas) [70], insulin-like
growth factor-binding protein-3 (overexpressed in non-
small cell lung cancer and breast cancer) [71, 72] and car-
cinoembryonic antigen-related cell adhesion molecule-6
(CEACAM6; overexpressed in colorectal carcinomas)
[73]. These genes might play an important role in PDAC,
too. The remaining 13 genes listed in table 3 have not
before been implicated to be involved in carcinogenesis.
Only 33 genes were found to be downregulated in pan-
creatic tumors in 2 or 3 of the 10 publications, respective-
ly, among them CD24 antigen and V-fos FBJ murine
osteosarcoma viral oncogene homolog. These two genes
had not been described to be of relevance in PDAC
before. Interestingly, however, CD24 was found to be an
independent prognostic marker in non-small cell lung
cancer patients [74]. Several genes, among them nucleo-
some assembly protein-1-like 1 (NAP1L1), showed dis-
crepant results. In two studies, NAP1L1 was described as
upregulated [47, 50], whereas a downregulated status was
detected with microdissected material [51].
Microarray Studies for Answering Clinical
Questions
Microarray technology has been proven to be feasible
in pancreatic tumors. Many novel candidate genes
emerged from the initial studies. On the other hand, so far
the expression profiles have not been proven to correlate
with individual cancer stages, grading and TMN classifi-
cation. Also, molecular differences between long- and
short-time survivors have not been detected. Most proba-
bly, however, this is mainly due to the small number of
samples in the studies mentioned above. New investiga-
tions are under way in several laboratories, including our
own, and will eventually provide the information neces-
sary. Already, the discrimination power of such analyses
was found to be sufficient to define new tumor entities on
the basis of their transcript profile [75].
The possibility of individualized medicine, the molec-
ular correlation between responders and non-responders
to adjuvant or neoadjuvant therapy, for example, is one of
the aims in this line of research. This, however, requires
carefully designed prospective profiling studies on
hundreds of patients, possibly focusing the analysis on
microdissected cells from normal and matched cancerous
pancreatic tissues. Moreover, the approach only analyzes
differences in the expression level of the genes, but not the
activity of proteins. Therefore, interesting candidate
genes have to be validated on the level of protein ac-
tivity.
Conclusions and Perspectives
Due to the human genome project, sequence informa-
tion of the entire human genome is available. In the form
of DNA microarrays, it can be utilized for global analyses
of gene expression. As opposed to earlier approaches, no
well-defined working hypothesis is required in this meth-
odology. It is a matter of comparing the transcript levels
between different tissues, or between healthy and dis-
eased tissue of the same kind. This approach exhibits both
advantages and weak points. A major advantage is the
fact that the analysis of gene expression is a totally unpre-
judiced process. No desires, assumptions or theories of
the experimenter are incorporated in the investigations.
Analysis and initial interpretation should be based purely
on statistical means. Also, no pre-selection of genes is tak-
ing place. One of the major drawbacks is the fact that fre-
quently the interpretation of the data is not immediately
feasible. Further, for the lack of a hypothesis, a reasonably
large amount of information has to be attained before a
statistically significant conclusion can be phrased.
In conclusion, microarray-based transcript analyses
have broadened our understanding of tumor biology.
These data will influence diagnostic and therapeutic strat-
egies for the treatment PDAC and other tumors. With the
great progress made in the handling and analysis of
microarrays, it can be assumed that more insights will
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soon be gained into the fundamental changes occurring
within a cancer cell. In future, and really not too far
ahead, microarray technology will be broadly introduced
into clinical practice. The discovery of novel therapeuti-
cally useful genes and diagnostic markers will fuel medical
progress and lead eventually to novel drugs and diagnostic
strategies.
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